Should You Buy the Dip on Compass Pathways Stock?
Morgan Stanley Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Cuts Target Price to $23
Morgan Stanley analyst Vikram Purohit maintains $COMPASS Pathways(CMPS.US)$ with a buy rating, and adjusts the target price from $30 to $23.According to TipRanks data, the analyst has a success rate o
Psychedelic Drug Stocks Plummet On FDA Advisers' Doubts About Ecstasy Candidate -- WSJ
By Liz Essley Whyte Stocks for companies developing psychedelic treatments fell Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA,
What's Going On With MindMed And Psychedelic Stocks?
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stre
Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating
COMPASS Pathways (CMPS) has an average rating of Buy and price targets ranging from $22 to $120, according to analysts polled by Capital IQ. Price: 6.59, Change: -1.08, Percent Change: -14.08
FDA advisory group refuses MDMA marketing authorization; psychedelic concept stocks slump.
The independent advisory group of the US FDA voted against the marketing authorization application for the psychiatric drug MDMA, causing a pre-market drop for the hallucinogenic drug developer.
Express News | Shares of Psychedelics Companies Are Trading Lower After an FDA Panel, on Tuesday, Rejected the Approval of MDMA Therapy for People With PTSD
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 50 points on Wednesday.Shares of DouYu International Holdings Limited (NASDAQ:DOYU) fell in today's pre-market trading
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersENDRA Life Sciences (NASDAQ:NDRA) stock increased by 71.6% to $0.15 during Wednesday's pre-market session. The company's market cap stands at $1.5 million. Concord Medical Services (NYSE:CCM) s
Psychedelic Stocks Fall as FDA Panel Rejects MDMA Therapy
FDA Advisory Panel Fails to Endorse Psychedelic MDMA Therapy for PTSD
TD Cowen Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23
TD Cowen analyst Ritu Baral maintains $COMPASS Pathways(CMPS.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 43.5% and a tot
GSK, Boston Beer And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.5% on Monday.Shares of GSK plc (NYSE:GSK) fell sharply in today's pre-market trading after the company said it will
Psychedelic Stocks Mixed as FDA Comments on MDMA Therapy
COMPASS Pathways(CMPS.US) 10% Shareholder Sells US$246.57K in Common Stock
$COMPASS Pathways(CMPS.US)$ 10% Shareholder Malievskaia Ekaterina sold 31,207 shares of common stock on May 20, 21, 2024 at an average price of $7.901 for a total value of $246.57K. This transaction i
These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring
Exploring Compass Pathways' (CMPS) After-Market Rally: Unveiling The Catalysts
During Thursday's after-market trading session, Compass Pathways plc (NASDAQ: CMPS) saw a notable spike in its shares. The stock was down 3.50% during the regular session, closing the extended session at $7.99, before closing at $8.34, up 4.38%. Given the absence of any significant news throughout the CMPS share movement, it's probable that current occurrences will ...
COMPASS Pathways Plc (NASDAQ:CMPS) Q1 2024 Earnings Call Transcript
Express News | HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $120 Price Target
Compass Pathways Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 1357.99% HC Wainwright & Co. → $120 Reiterates Buy → Buy 04/30/2024 — Cantor Fitzgerald Reiter
No Data